Short Interest in AB Corporate Bond ETF (NASDAQ:EYEG) Expands By 568.4%

AB Corporate Bond ETF (NASDAQ:EYEG) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 655 shares, a growth of 568.4% from the July 15th total of 98 shares. Based on an average trading volume of 295 shares, the short-interest ratio is presently 2.2 days. Approximately 0.0% of the shares of the company are sold short.

Hedge Funds Weigh In On AB Corporate Bond ETF

An institutional investor recently bought a new stake in AB Corporate Bond ETF stock. Kestra Advisory Services LLC bought a new stake in shares of AB Corporate Bond ETF (NASDAQ:EYEG) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 951 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. Kestra Advisory Services LLC owned about 0.13% of AB Corporate Bond ETF at the end of the most recent quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

AB Corporate Bond ETF Stock Performance

EYEG stock traded up $0.12 during trading on Thursday, reaching $34.66. The stock had a trading volume of 1,298 shares, compared to its average volume of 258. AB Corporate Bond ETF has a 52 week low of $34.46 and a 52 week high of $36.63. The stock’s 50 day moving average is $34.97 and its two-hundred day moving average is $35.29. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. The firm has a market cap of $27.73 million, a PE ratio of -20.63 and a beta of 0.18.

AB Corporate Bond ETF Increases Dividend

The firm also recently disclosed a monthly dividend, which was paid on Thursday, August 6th. Stockholders of record on Monday, August 3rd were paid a $0.1427 dividend. This is a boost from AB Corporate Bond ETF’s previous monthly dividend of $0.14. The ex-dividend date was Monday, August 3rd. This represents a c) annualized dividend and a dividend yield of 4.9%. AB Corporate Bond ETF’s dividend payout ratio (DPR) is currently -102.38%.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.